A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Shortly after scoring a historic FDA nod for its Wegovy pill, Novo Nordisk is off to the races with the oral obesity med’s launch. The once-daily pill officially debuted in the U.S. Monday, with the ...

Novo Nordisk’s NOVO.B1.17%increase; green up pointing triangle Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish ...

Novo Nordisk’s (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively ...

American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices for the drug, called the Wegovy ...

Novo launches Wegovy pill in competitive obesity drug market Eli Lilly expects weight-loss pill decision later this year Novo targets self-pay market with oral option over injectable Starter dose of ...

The Wegovy pill is the first and only oral GLP-1 for weight loss in adults. The first and only oral GLP-1 for weight loss in adults is now available to consumers. Drugmaker Novo Nordisk announced ...

Its newly earned indications could impact financial results in 2026. The drugmaker should also make decent pipeline progress. Novo Nordisk's shares look reasonably valued. Thankfully, 2026 could be a ...

Novo Nordisk’s wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the United States. The pill is available in four doses and is cheaper ...

Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than its peer. Even considering its seemingly more reasonable valuation, Novo ...

For years, pharmaceutical companies have been racing to develop a market-ready GLP-1 weight-loss pill to join the ranks of popular injectables. Today, Novo Nordisk’s oral version of Wegovy is ...